Uremic Pruritus Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc.

Uremic Pruritus Pipeline constitutes 2+ key companies continuously working towards developing 2+ Uremic Pruritus treatment therapies, analyzes DelveInsight.

Uremic Pruritus Overview:

Uremic pruritus (UP), also known as chronic kidney disease-associated pruritus (CKD-aP), is a common and distressing condition in patients with advanced chronic kidney disease (CKD), particularly those on dialysis. It is characterized by persistent itching, often without a clear dermatological cause, and can significantly affect a patient's quality of life. The exact cause is not fully understood but is believed to be linked to systemic inflammation, metabolic imbalances, and the accumulation of uremic toxins due to impaired kidney function.

The primary symptom is intense, persistent itching, which can occur anywhere on the body or be localized to areas like the back, arms, or face. The itching is often worse at night, disrupting sleep and causing fatigue. There are typically no visible skin changes early on, but chronic scratching can result in secondary lesions and skin thickening. Uremic pruritus often occurs alongside other CKD symptoms, such as dry skin and muscle cramps.

Diagnosis is primarily clinical, based on a patient's CKD history and persistent itching without an obvious cause. Physicians rule out other potential causes, such as allergies or dermatological conditions, through exams and tests. While there is no cure, treatment aims to manage symptoms and improve quality of life. Approaches include optimizing dialysis to reduce uremic toxins, using topical emollients for dry skin, and employing antihistamines or gabapentinoids to reduce itching. Systemic treatments like opioid receptor modulators (e.g., nalfurafine), corticosteroids, and phototherapy (narrowband UVB) may also provide relief.

Request for a detailed insights report on Uremic Pruritus pipeline insights @ https://www.delveinsight.com/report-store/uremic-pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Uremic Pruritus Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Uremic Pruritus Therapeutics Market.

Key Takeaways from the Uremic Pruritus Pipeline Report

DelveInsight's Uremic Pruritus pipeline report depicts a robust space with 2+ active players working to develop 2+ pipeline therapies for Uremic Pruritus treatment.
Key Uremic Pruritus companies such as Qilu Pharmaceutical, and others are evaluating new drugs for Uremic Pruritus to improve the treatment landscape.
Promising Uremic Pruritus pipeline therapies in various stages of development include QLG2198, and others.

Recent breakthroughs in the Uremic Pruritus Pipeline Segment:

Lumosa Therapeutics is developing LT5001, a topical ointment containing dinalbuphine sebacate (DNS), designed to alleviate pruritus. DNS acts as a kappa-opioid receptor agonist and mu-opioid receptor antagonist, aiming to reduce itching without significant systemic absorption. This formulation offers a convenient application for patients.
The U.S. Food and Drug Administration (FDA) approved difelikefalin, marketed as Korsuva, for the treatment of moderate to severe pruritus in adults undergoing hemodialysis. This approval marked the first FDA-endorsed treatment specifically targeting uremic pruritus, offering relief to patients who previously had limited options.

Uremic Pruritus Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Uremic Pruritus Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uremic Pruritus treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Uremic Pruritus market.

Download our free sample page report on Uremic Pruritus pipeline insights @ https://www.delveinsight.com/sample-request/uremic-pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Uremic Pruritus Emerging Drugs

QLG2198: Qilu Pharmaceutical

Uremic Pruritus Companies

Around 2 or more key companies are working on developing therapies for uremic pruritus. Among them, Qilu Pharmaceutical has drug candidates for uremic pruritus in the most advanced stage, specifically Phase III.

DelveInsight's report covers around 2+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Uremic Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Uremic Pruritus Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Uremic Pruritus Therapies and Key Companies: Uremic Pruritus Clinical Trials and advancements @ https://www.delveinsight.com/report-store/uremic-pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Uremic Pruritus Pipeline Therapeutic Assessment
• Uremic Pruritus Assessment by Product Type
• Uremic Pruritus By Stage
• Uremic Pruritus Assessment by Route of Administration
• Uremic Pruritus Assessment by Molecule Type

Download Uremic Pruritus Sample report to know in detail about the Uremic Pruritus treatment market @ Uremic Pruritus Therapeutic Assessment @ https://www.delveinsight.com/sample-request/uremic-pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Uremic Pruritus Current Treatment Patterns
4. Uremic Pruritus - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Uremic Pruritus Late-Stage Products (Phase-III)
7. Uremic Pruritus Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Uremic Pruritus Discontinued Products
13. Uremic Pruritus Product Profiles
14. Uremic Pruritus Key Companies
15. Uremic Pruritus Key Products
16. Dormant and Discontinued Products
17. Uremic Pruritus Unmet Needs
18. Uremic Pruritus Future Perspectives
19. Uremic Pruritus Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Uremic Pruritus Pipeline Reports Offerings: https://www.delveinsight.com/report-store/uremic-pruritus-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.